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Abstract
Background: The Apo-1/Fas (CD95) molecule is an apoptosis-signaling cell surface receptor
belonging to the tumor necrosis factor (TNF) receptor family. Both Fas and Fas ligand (FasL) are
expressed in activated mature T cells, and prolonged cell activation induces susceptibility to Fas-
mediated apoptosis. The Apo-1/Fas gene is located in a chromosomal region that shows linkage in
multiple sclerosis (MS) genome screens, and studies indicate that there is aberrant expression of
the Apo-1/Fas molecule in MS.
Methods: Mva I polymorphism on the Apo-1/Fas promoter gene was detected by PCR-RFLP from
the DNA of 114 Japanese patients with conventional MS and 121 healthy controls. We investigated
the association of the Mva I polymorphism in Japanese MS patients using a case-control association
study design.
Results: We found no evidence that the polymorphism contributes to susceptibility to MS.
Furthermore, there was no association between Apo-1/Fas gene polymorphisms and clinical course
(relapsing-remitting course or secondary-progressive course). No significant association was
observed between Apo-1/Fas gene polymorphisms and the age at disease onset.
Conclusions: Overall, our findings suggest that Apo-1/Fas promoter gene polymorphisms are not
conclusively related to susceptibility to MS or the clinical characteristics of Japanese patients with
MS.
Background
Apoptosis is a physiologic process that regulates normal
homeostasis and is likely to contribute to the pathogene-
sis of autoimmune diseases by impairing elimination of
autoreactive T and B cells [1]. Physiologic regulation of
cell death is essential for removal of potentially autoreac-
tive lymphocytes during development and excess cells af-
ter the completion of an immune response. Apo-1/Fas,
also known as CD95, is a 36-kDa transmembrane glyco-
protein expressed on the surface of many cell types, such
as lymphocytes, epithelial cells, fibroblasts, and certain
endothelial cells. Apo-1/Fas mediates apoptosis of these
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regulated and restricted to activated T cells, NK cells, and
at sites of immune privilege [3]. Apo-1/Fas is considered
to have an important role in the regulation of the immune
system by deleting autoreactive lymphocytes. Inadequate
co-stimulation of T cells by antigen-presenting glial cells
might render T cells susceptible to activation-induced ap-
optosis. T cells expressing Apo-1/Fas might also die in an
antigen-nonspecific manner after interacting with glial
cells expressing Apo-1/FasL. T-cell apoptosis contributes
to resolution of the central nervous system (CNS) inflam-
mation and clinical recovery from attacks of experimental
autoimmune encephalomyelitis (EAE), an animal model
of multiple sclerosis (MS) [4]. Apoptosis of autoreactive T
cells in the CNS is likely to be important in preventing the
development of MS [5]. On the other hand, Apo-1/Fas
mRNA and protein are both induced after UV light expo-
sure [6], indicating that the regulation of this gene is im-
portant in the cellular response to UV light. The
geographic distribution of MS might be related to the de-
gree of sunlight exposure, and exposure to UV light might
have a protective effect in MS. Taken together, Apo-1/Fas
is a candidate proapoptotic gene in MS.
Apo-1/Fas is a type I transmembrane protein that belongs
to the tumor necrosis factor receptor superfamily
(TNFRSF), and maps to the long arm of chromosome
10q23/10q24.1 in humans [7,8]. Positive lod scores with
microsatellite markers near this region were identified in
the United States [9] and Canadian genome screens [10].
The gene encoding Apo-1/Fas, TNFRSF6, contains a single
nucleotide polymorphism (SNP) in the promoter at posi-
tion -670 that disrupts a gamma-activated sequence
(GAS) transcription factor binding sequence [11]. This
polymorphism creates an Mva I restriction fragment
length polymorphism (RFLP), and abolishes the binding
site of the nuclear transcription element, GAS. The func-
tion of the polymorphism remains unclear, but its loca-
tion, on a consensus sequence of the GAS, implies that it
might be associated with altered Fas gene transcription.
In the present study, we examined the association of the
promoter -670 polymorphism in the Apo-1/Fas gene in
Japanese patients with MS.
Patients and Methods
Patients and healthy individuals
Unrelated patients (n = 114) with relapsing-remitting type
MS (RRMS) or secondary-progressive type MS (SPMS)
who, after having been observed for at least 1 year, were
diagnosed as MS according to the criteria of McDonald
[12] (Table 1). The patients were considered "convention-
al" MS patients, which were quite similar clinically to
Western MS patients, and "optic-spinal form" MS patients
were excluded from this study [13]. The control group was
composed of 29 unrelated healthy men and 92 unrelated
healthy women ranging from 20 to 58 years old (mean ±
SD; 33.1 ± 9.2). All of the patients and controls were Jap-
anese and were residents of Hokkaido, the northernmost
island of Japan. There were no significant differences in
the sex ratio and age between the patients and controls.
This study was performed in accordance with the ethical
standards laid down in the 1964 Declaration of Helsinki.
Genotyping of the polymorphism at position -670
After obtaining the informed consent of each subject, high
molecular weight DNA was extracted from their peripher-
al blood cells. Apo-1/Fas promoter Mva I polymorphisms
were determined by polymerase chain reaction-restriction
fragment length polymorphism (PCR-RFLP) using DNA,
according to previously described methods [11]. The Mva
I restriction enzyme detected a dimorphism with either a
band at 189 bp (allele G) or a band at 233 bp (allele A)
from PCR products.
Genomic HLA-DRB1 typing
The genomic HLA typing methods were previously de-
scribed [14]. In this study, DRB1 alleles were determined
in 107 MS patients and 103 controls.
Statistical analysis
Comparisons between the various alleles of patients with
MS and controls were made using the Chi-square test for
two-by-two or two-by-three comparisons. The statistical
analysis between the genotypes of Mva I polymorphism
and the onset age of MS patients was tested by analysis of
variance (ANOVA) followed by Fisher's protected least
significant difference (PLSD).
Table 1: Clinical profiles of MS patients
Total (n = 114)
Female : Male 84 : 30
Age (mean years ± SD) 35.0 ± 10.7
Age at onset (mean years ± SD) 26.2 ± 9.0
Course
relapsing-remitting type 79 (69.3%)
secondary-progressive type 35 (30.7%)
Duration (mean years ± SD) 8.9 ± 8.4
EDSS (mean ± SD) 3.0 ± 2.5
HLA-DRB1*1501 allele positive 34/107 (31.8%)
EDSS; Expanded Disability Status Scale of KurtzkePage 2 of 5
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Mva I genotype and allele frequencies
The proportions of Mva I genotypes in the Apo-1/Fas pro-
moter gene in the MS patients and controls are shown in
Table 2. In the control subjects, the genotype frequencies
conformed to Hardy-Weinberg expectations. There was
no significant difference in the distributions of Mva I pol-
ymorphisms between MS patients and the control group.
Among the 114 MS patients, there was no association be-
tween the Mva I gene polymorphisms and the clinical
course (relapsing-remitting course or secondary progres-
sive course).
The association between Mva I polymorphism and age at 
disease onset
In the relation between Mva I polymorphism and age at
onset of MS, the mean onset ages of the patients with G/
G, G/A, and A/A genotypes were (age ± SD) : 25.0 ± 9.5,
25.4 ± 7.7, and 29.1 ± 11.2, respectively (Table 3). Pa-
tients with the A/A genotype tended to have a later onset
than those with the G/G or G/A genotype, but this differ-
ence was not statistically significant (P = 0.168).
Mva I polymorphism in DRB1*1501 positive and negative 
individuals
The positive rates of HLA-DRB1*1501 in MS patients and
controls were 34/107 (31.8%) and 15/103 (14.6%), re-
spectively. The positive rate of DRB1*1501 in MS patients
was significantly higher than that in controls (P < 0.005).
The Mva I genotype and allele frequencies in the MS pa-
tients and in controls positive and negative for the
DRB1*1501 allele are shown in Table 4. There were no
significant differences in the Mva I allele and genotype fre-
quencies in DRB1*1501 positive or negative patients.
Discussion
We analyzed a new genetic marker, Mva I polymorphism
on the Fas promoter gene, in patients with MS. There were
no differences in genotype or allele frequencies among MS
patients and controls. Furthermore, our results indicated
that Mva I polymorphisms are not associated with the
clinical course (relapsing-remitting course or secondary
progressive course). Patients with the A/A genotype tend-
ed to have a later onset than those with the G/G or G/A
genotype but this difference was not statistically signifi-
cant. To date, there has been one report regarding this Mva
I polymorphism and MS [15]. In that report in Australian
population, there were increases in the A allele in MS in-
dividuals overall, and in HLA-DRB1*1501 negative MS
patients [15]. This tendency was not detected in the Japa-
nese MS individuals in the present study.
Table 2: Apo-1/Fas promoter polymorphism at position -670 in the enhancer region: Case-control analysis of genotype and alleles
MS patients Controls
Total R-R S-P
N = 114 (%) N = 79 (%) N = 35 (%) N = 121 (%)
Genotype frequency
G/G 23 (20.2%) 16 (20.3%) 7 (20.0%) 25 (20.7%)
G/A 65 (57.0%) 44 (55.7%) 21 (60.0%) 63 (52.1%)
A/A 26 (22.8%) 19 (24.1%) 7 (20.0%) 33 (27.3%)
Allele frequency
G 111 (48.7%) 76 (48.1%) 35 (50.0%) 113 (46.7%)
A 117 (51.3%) 82 (51.9%) 35 (50.0%) 129 (53.3%)
There was no significant difference in the distributions of -670 polymorphisms in Apo-1/Fas gene between MS patients and control subjects. Fur-
thermore, there were no significant differences in the distributions of -670 polymorphisms in the Apo-1/Fas gene between patients with a relapsing-
remitting course and those with a secondary-progressive course or between patients with either course and controls (P > 0.05).
Table 3: Age at disease onset in Apo-1/Fas promoter polymor-
phism at position -670
Genotype No. of patients Age at 
onset 
(mean age ± 
S.D.)
G/G 23 25.0 ± 9.5
G/A 65 25.4 ± 7.7
A/A 26 29.1 ± 11.2
Statistical analysis was performed using ANOVA. There was a trend 
for patients with the A/A genotype to have a later onset than patients 
with the G/G or G/A genotype, but the difference was not statistically 
significant (P = 0.168).Page 3 of 5
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moter -670 polymorphism and autoimmune diseases or
degenerative diseases. Huang et al. demonstrated a
skewed distribution of Mva I genotypes in the first cohort
of 103 Australian patients with rheumatoid arthritis (RA),
but this association was not confirmed in a second cohort
[16]. The -670 polymorphism is associated with develop-
ment of anti-RNP antibodies in systemic lupus erythema-
tosus (SLE) [17]. The -670 polymorphism is also
associated with Alzheimer's disease and interacts with the
APO-E variant [18], indicating that it has potential biolog-
ic significance.
MS is considered to be an autoimmune disorder of un-
known etiology. The pathogenesis of the disease remains
obscure, but genetic factors are considered to be contribu-
tory. In the HLA, there was an association between
DRB1*1501 and MS in our study as well as in Caucasian.
With respect to the genetics of MS, it is possible that non-
HLA genes have a pathogenetic role. Because a case-con-
trol study design might provide spurious results attributa-
ble to population stratification, including negative
findings such as those reported in the present study, addi-
tional studies are necessary to exclude the possibility of
type 2 errors. Population association studies that compare
the frequency of variants between cases and controls
might be particularly effective and might be a powerful as-
say for common genetic variants of weak effect [19]. While
our results are not entirely consistent with those of anoth-
er report examining other ethnicities [15], this inconsist-
ency might be due, in part, to differences in the
polymorphism background of the different ethnic group.
Further research in gene polymorphisms present in other
ethnic groups is needed, as well as further research in the
Japanese patient group. In addition, susceptibility genes
might provide a small individual contribution in MS, thus
their identification might be important for providing
clues to the pathogenesis of the different clinical forms of
the disease and for designing the most effective therapy
for each individual patient.
Conclusions
We investigated Mva I polymorphism on the Apo-1/Fas
promoter gene from the DNA of 114 Japanese patients
with conventional MS and 121 healthy controls. We
found no evidence that the polymorphism contributes to
susceptibility to MS. Furthermore, there was no associa-
tion between Apo-1/Fas gene polymorphisms and clinical
course (relapsing-remitting course or secondary-progres-
sive course). No significant association was observed be-
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Table 4: Genotype and allele frequencies of the Apo-1/Fas Mva I polymorphism in thepresence and absence of the DRB1*1501
DRB1*1501 positive DRB1*1501 negative
MS patients N = 34 (%) Controls N = 15 (%) MS patients N = 73 (%) Controls N = 88 (%)
Genotype frequency
G/G 13 (38.2%) 3 (20.0%) 15 (20.5%) 20 (22.7%)
G/A 14 (41.2%) 8 (53.3%) 47 (64.4%) 48 (54.5%)
A/A 7 (20.6%) 4 (26.7%) 11 (15.1%) 20 (22.7%)
Allele frequency
G 40 (58.8%) 14 (46.7%) 77 (52.7%) 88 (50.0%)
A 28 (41.2%) 16 (53.3%) 69 (47.3%) 88 (50.0%)
The positive rates of HLA-DRB1*1501 in MS patients and controls were 34/107 (31.8%) and 15/103 (14.6%), respectively. The positive rate of 
DRB1*1501 in MS patients was significantly higher than that in controls (P < 0.005). There was no significant difference in the distributions of -670 
polymorphisms in the Apo-1/Fas gene in DRB1*1501 positive or negative MS patients. (P > 0.05).Page 4 of 5
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